{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=11",
    "query": {
      "intervention": "fludarabine",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 1451,
    "total_pages": 146,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T02:27:26.630Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03263559",
      "title": "Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Haploidentical Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Rabbit-ATG",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "5 Years to 45 Years"
      },
      "enrollment_count": 95,
      "start_date": "2017-10-03",
      "completion_date": "2025-01-29",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Oakland, California • Aurora, Colorado + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263559"
    },
    {
      "nct_id": "NCT02905188",
      "title": "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "GLYCAR T cells",
          "type": "GENETIC"
        },
        {
          "name": "Cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2019-03-28",
      "completion_date": "2023-01-06",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02905188"
    },
    {
      "nct_id": "NCT00305682",
      "title": "Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2005-06",
      "completion_date": "2019-12-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305682"
    },
    {
      "nct_id": "NCT00044954",
      "title": "Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-11",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 14,
      "location_summary": "Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044954"
    },
    {
      "nct_id": "NCT03836261",
      "title": "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Chemoimmunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 984,
      "start_date": "2019-02-25",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Redondo Beach, California • Fort Wayne, Indiana + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03836261"
    },
    {
      "nct_id": "NCT03070327",
      "title": "BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "EGFRt/BCMA-41BBz CAR T cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-02-27",
      "completion_date": "2026-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070327"
    },
    {
      "nct_id": "NCT03190941",
      "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Gastrointestinal Cancer",
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Anti-KRAS G12V mTCR PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 110,
      "start_date": "2017-09-21",
      "completion_date": "2028-06-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190941"
    },
    {
      "nct_id": "NCT00427661",
      "title": "A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "Busulfan; Fludarabine; cyclosporine A and MMF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "3 Years to 35 Years"
      },
      "enrollment_count": 8,
      "start_date": "2002-06",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-18",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00427661"
    },
    {
      "nct_id": "NCT03704298",
      "title": "Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Utomilumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-11-20",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03704298"
    },
    {
      "nct_id": "NCT07604233",
      "title": "Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Asciminib",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-11-30",
      "completion_date": "2033-06-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-25T02:27:26.630Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07604233"
    }
  ]
}